Genomic Profiling of Prostate Cancers from Men with African and European Ancestry
- 10 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (17), 4651-4660
- https://doi.org/10.1158/1078-0432.ccr-19-4112
Abstract
Purpose: African American (AFR) men have the highest mortality rate from prostate cancer (PCa) compared with men of other racial/ancestral groups. Differences in the spectrum of somatic genome alterations in tumors between AFR men and other populations have not been well-characterized due to a lack of inclusion of significant numbers in genomic studies. Experimental Design: To identify genomic alterations associated with race, we compared the frequencies of somatic alterations in PCa obtained from four publicly available datasets comprising 250 AFR and 611 European American (EUR) men and a targeted sequencing dataset from a commercial platform of 436 AFR and 3018 EUR men. Results: Mutations in ZFHX3 as well as focal deletions in ETV3 were more frequent in tumors from AFR men. TP53 mutations were associated with increasing Gleason score. MYC amplifications were more frequent in tumors from AFR men with metastatic PCa, whereas deletions in PTEN and rearrangements in TMPRSS2-ERG were less frequent in tumors from AFR men. KMT2D truncations and CCND1 amplifications were more frequent in primary PCa from AFR men. Genomic features that could impact clinical decision making were not significantly different between the two groups including tumor mutation burden, MSI status, and genomic alterations in select DNA repair genes, CDK12, and in AR. Conclusions: Although we identified some novel differences in AFR men compared with other populations, the frequencies of genomic alterations in current therapeutic targets for PCa were similar between AFR and EUR men, suggesting that existing precision medicine approaches could be equally beneficial if applied equitably.Keywords
Other Versions
Funding Information
- Department of Defense (W81XWH-14-1-0514)
- Department of Defense (W81XWH-17-PCRP-HD)
- NIH NCI (P20 CA233255-01)
- NIH NCI (U19 CA214253)
This publication has 32 references indexed in Scilit:
- Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER studyPLOS ONE, 2015
- DNA-Repair Defects and Olaparib in Metastatic Prostate CancerThe New England Journal of Medicine, 2015
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyThe Lancet Oncology, 2015
- Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian MenClinical Cancer Research, 2014
- Deletion of Atbf1/Zfhx3 In Mouse Prostate Causes Neoplastic Lesions, Likely by Attenuation of Membrane and Secretory Proteins and Multiple Signaling PathwaysNeoplasia, 2014
- Contribution of p53 to MetastasisCancer Discovery, 2014
- Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERβ) in human prostate cancerThe Prostate, 2012
- Fast model-based estimation of ancestry in unrelated individualsGenome Research, 2009
- Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American menProceedings of the National Academy of Sciences of the United States of America, 2006